Effect of remazolam toluene sulfonate on postoperative delirium in debilitating patients under general anesthesia, a prospective cohort study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400084475

Enrollment

Unknown

Registered

2024-05-17

Start date

2024-06-01

Completion date

Unknown

Last updated

2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative delirium

Interventions

Remazolam group/ Without remazolam group:None

Eligibility

Sex/Gender

All

Age

50 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1) Age 50-90 years; 2) preoperative assessment of Frailty with the CFS (Clinical Frailty Scale) , Patientsents who met the criteria for Frailty (=5 points) without any of the exclusion criteria were eligible for inclusion; 3) to operate under general anesthesia;

Exclusion criteria

Exclusion criteria: 1) participated in other studies in the last 1 month; 2) continuous use of benzodiazepine for more than 1 week within 1 month before surgery 3) previous history of schizophrenia, epilepsy, Parkinson's disease or myasthenia gravis;

Design outcomes

Primary

Measure	Time frame
Incidence of delirium within 3 days after surgery;	—

Countries

China

Contacts

Public ContactYang Yanjie

The Second Hospital of Hebei Medical University

yangyanjie2010@163.com+86 150 0321 8859

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026